From Our Blog
Here’s a Little of What We’ve Learned Over the Years!
The Journal of the Canadian Association of Gastroenterology has newly published guidelines for the management of irritable bowel syndrome (IBS) in adults in its April 2019 issue. Twelve named authors from the fields of gastroenterology, health psychology and primary care, represent six Canadian universities…
U.S. FDA Approves Return of Tegaserod (Zelnorm) to U.S. Market for Some Women with IBS-C, April 2019
At the end of March 2019, the U.S Food and Drug Administration (FDA) approved the reintroduction of tegaserod (brand name Zelnorm), an oral medication for irritable bowel syndrome with constipation (IBS-C) to the U.S., only for women without risk factors for or history of…
According to news releases, the Canadian branch of Lupin Pharmaceuticals, the distributor of Rifaximin, recently announced that Health Canada, the Canadian drug regulatory agency, has approved its use for irritable bowel syndrome with diarrhea (IBS-D). Rifaximin, which is manufactured by Salix Pharmaceuticals in the…
The International Foundation for Functional Gastrointestinal Disorders (IFFGD) is an established, reputable U.S. based 501c3 not-for-profit organization/charity focused on irritable bowel syndrome (IBS) and related functional gastrointestinal disorders, also known as disorders of gut-brain interaction. IFFGD was founded in 1991 by an FGID-affected family…
In April 2018, the journal Gastroenterology reported that an international collaboration of researchers headed by the Karolinska Institutet in Sweden, has identified several DNA variants on Chromosome 9 that may be associated with higher risk of IBS in women, particularly IBS with constipation. This…
In April 2018, in time for IBS Awareness Month, the Gastrointestinal Society in Canada released a 38 page 2018 IBS Global Impact Report, which is available for download on its website. This report was funded and facilitated by the international pharmaceutical company Allergan, and…
On January 30, 2018, the U.S. Food and Drug Administration (FDA) which regulates the approval and distribution of medications in the U.S, issued a drug safety communication for the anti-diarrheal medication loperamide. Loperamide is more commonly recognized by the public by the brand name…
In January 2018, plecanatide, also known by the brand name Trulance, and previously available in the United States for use in chronic idiopathic constipation, was approved by the U.S. Food and Drug Administration (FDA) for treatment of irritable bowel syndrome with constipation (IBS-C). See…
In mid-October, fashion designer Mychael Knight, who was a former star of the U.S. reality television show “Project Runway,” passed away at the age of 39. It is unfortunate that he apparently suffered from chronic gastrointestinal issues that may or may not have contributed…
One of the interesting and groundbreaking articles presented this year at Digestive Disease Week, an annual international gastroenterology professional conference in May 2017 is a collaboration of 14 researchers from UCLA, Texas Children’s Microbiome Center and Baylor College of Medicine, and the Washington University…